
|Videos|September 24, 2021
Dr. McVary discusses individualizing care in men with BPH
Author(s)Urology Times staff
“[BPH treatment] has to be individualized to the motivations of the patient, and also what I call his "phenotype.” How big is his prostate? How bad is this problem? And what is his tolerance for side effects?” says Kevin T. McVary, MD.
Advertisement
In this video, Kevin McVary, MD, FACS, discusses his patient selection process for BPH clinical trials and the importance of individualized care. McVary is a professor of urology and director of the Center for Male Health at Loyola University Medical Center, Maywood, Illinois.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
2
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
3
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
4
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
5










